New hope for advanced colorectal cancer: experimental drug tested in china

NCT ID NCT06464692

First seen May 25, 2026 ยท Last updated May 25, 2026

Summary

This early-stage study tests an experimental drug called telisotuzumab adizutecan in about 30 Chinese adults with advanced colorectal cancer that cannot be removed by surgery. The main goals are to check safety and how the drug moves through the body. Participants receive different doses of the drug through an IV, and researchers will monitor side effects and tumor response.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary โ€” we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for COLORECTAL CANCER are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Locations

  • Beijing Cancer Hospital /ID# 263297

    Beijing, Beijing Municipality, 100142, China

  • First Affiliated Hospital of China Medical University /ID# 263338

    Shenyang, Liaoning, 110001, China

  • Harbin Medical University Cancer Hospital /ID# 263049

    Harbin, Heilongjiang, 150081, China

  • Henan Cancer Hospital /ID# 263172

    Zhengzhou, Henan, 450008, China

  • Hubei Cancer Hospital /ID# 263248

    Wuhan, Hubei, 430079, China

  • The First Affiliated Hospital of Nanchang University /ID# 263193

    Nanchang, Jiangxi, 330006, China

  • The Second Affiliated Hospital of College of Medicine - Zhejiang University /ID# 263094

    Hangzhou, Zhejiang, 310000, China

  • The Sixth Affiliated Hospital of Sun Yat-sen University /ID# 263309

    Guangzhou, Guangdong, 510655, China

Conditions

Explore the condition pages connected to this study.